Need professional-grade analysis? Visit stockanalysis.com
$311.29B
35.78
6,731
N/A
Emcure Pharmaceuticals Ltd (EMCURE) trades on NSE in INR. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at INR1672.10, up 2.02% from the previous close.
Over the past year, EMCURE has traded between a low of INR1271.80 and a high of INR1672.10. The stock has gained 19.6% over this period. It is currently 31.5% above its 52-week low.
Emcure Pharmaceuticals Ltd has a market capitalization of $311.29B, with a price-to-earnings ratio of 35.78.
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.
Side-by-side comparison against top Healthcare peers.